Clinical Trial Update: The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

View source ↗

Summary

Real-world study in France evaluating glycemic control using Tandem's Control-IQ technology and its impact on quality of life in people with Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Snippet

Sponsor: Tandem Diabetes Care, Inc. | Conditions: Diabetes Mellitus, Type 1 | Status: RECRUITING